Prednisone News and Research

RSS

High-dose glucocorticoids double risk of bacterial infections in children with JIA

Children with juvenile idiopathic arthritis have higher rates of bacterial infection requiring hospitalization, and use of high-dose steroids significantly increases that risk, according to research from the University of Alabama at Birmingham.

2 May 2012

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

2 May 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.

6 Apr 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012

New ACR classification criteria for polymyalgia rheumatica

The American College of Rheumatology has released the first classification criteria for polymyalgia rheumatica - aimed at helping physicians identify patients with this condition, which occurs in persons aged 50 years or older who have recent onset of pain in the shoulders, neck and hips along with other inflammatory symptoms not explained by an alternate diagnosis.

2 Mar 2012

Questcor fourth quarter net sales increase to $75.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2011.

22 Feb 2012

New immunotherapy combination prolongs survival in dogs with NHL

A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports.

8 Feb 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

Rapid discontinuation of prednisone after kidney transplant can help prevent side effects

Rapid discontinuation of the immunosuppressive steroid prednisone after a kidney transplant can help prevent serious side effects, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

27 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Abiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel.

7 Jan 2012

$Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer$

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.

4 Jan 2012

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Amgen today announced the U.S. Food and Drug Administration has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

30 Dec 2011

Soligenix reports results from orBec Phase 2 trial on acute GVHD

Soligenix, Inc., a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

12 Dec 2011

BioInvent announces new BI-505 preclinical data on multiple myeloma

BioInvent International AB announced today that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density.

12 Dec 2011

New cancer research findings presented at 53rd ASH annual meeting

Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

12 Dec 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

TNF inhibitors may minimally increase risk of serious infections

Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infections from using them. But new research from the University of Alabama at Birmingham Center for Education and Research on Therapeutics reveals that a class of biologics called tumor necrosis factor antagonists, or TNF inhibitors, may only minimally increase risk compared to more traditional therapies.

17 Nov 2011

Vitamin D supplementation benefits people with lupus

The first study to report the effects vitamin D has on the immune system of people with lupus was reported this week a the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Prednisone News and Research

High-dose glucocorticoids double risk of bacterial infections in children with JIA

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

New ACR classification criteria for polymyalgia rheumatica

Questcor fourth quarter net sales increase to $75.5 million

New immunotherapy combination prolongs survival in dogs with NHL

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Rapid discontinuation of prednisone after kidney transplant can help prevent side effects

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Soligenix reports results from orBec Phase 2 trial on acute GVHD

BioInvent announces new BI-505 preclinical data on multiple myeloma

New cancer research findings presented at 53rd ASH annual meeting

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

TNF inhibitors may minimally increase risk of serious infections

Vitamin D supplementation benefits people with lupus

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News